朗坤科技(301305.SZ)：控股子公司研发的2’-FL获得国家卫生健康委员会批准

Core Viewpoint - Longkun Technology (301305.SZ) has received approval from the National Health Commission for its self-developed human milk oligosaccharides (HMOs) product 2'-FL (2'-fucosyllactose), marking a significant milestone in the domestic HMO industry [1] Group 1 - The approval of 2'-FL follows the earlier approval of LNnT (lactose-N-tetraose), making it the second core HMO component approved in China [1] - This achievement represents an important advancement in the company's innovative research and compliance layout for the entire HMO value chain [1] - The approval is a key milestone for promoting the independent and large-scale development of the domestic HMO industry [1]